Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: The ProtecT study

Cancer Causes and Control

Volumn 24, Issue 2, 2013, Pages 323-334

  Burton, Anya ^a,b   Martin, Richard M ^a,b   Holly, Jeff ^b   Lane, J Athene ^a   Donovan, Jenny L ^a   Hamdy, Freddie C ^c   Neal, David E ^d   Tilling, Kate ^a  

^a University of Bristol Canynge Hall   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adiponectin; Body mass index; Leptin; Progression; Prostate cancer; Stage

Indexed keywords

ADIPONECTIN; LEPTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ADIPONECTIN; AGED; CASE-CONTROL STUDIES; HUMANS; LEPTIN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84878828308     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0118-4     Document Type: Article

References (53)

1. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 Lyon. International Agency for Research on Cancerm, France
2. World Health Organisation (2006) Global database on body mass index. http://apps.who.int/bmi/index.jsp. Accessed 21 Aug 2012
3. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G (2008) The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15:3866-3871
4. Pashayan N, Duffy SW, Pharoah P, et al. (2009) Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 100:1198-1204
5. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) (2011) SEER Cancer statistics review, 1975-2008. National Cancer Institute, Bethesda, http://seer.cancer.gov/csr/1975- 2008/, based on November 2010 SEER data submission
6. McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159:1368-1372
7. Hugosson J, Carlsson S, Aus G, et al. (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732
8. Schroder FH, Hugosson J, Roobol MJ, et al. (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990
9. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578
10. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Philadelphia, PA) 4:486-501
11. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17:989-1003
12. Somasundar P, Frankenberry KA, Skinner H, et al. (2004) Prostate cancer cell proliferation is influenced by leptin. J Surg Res 118:71-82
13. Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H, Masaki Z (2003) Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 91:716-720
14. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188:560-565
15. Sierra-Honigmann MR, Nath AK, Murakami C, et al. (1998) Biological action of leptin as an angiogenic factor. Science 281:1683-1686
16. Bub JD, Miyazaki T, Iwamoto Y (2006) Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340:1158-1166
17. Brakenhielm E, Veitonmaki N, Cao R, et al. (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101:2476-2481
18. Mistry T, Digby JE, Desai KM, Randeva HS (2008) Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. Bju Int 101:1317-1322
19. Li H, Stampfer MJ, Mucci L, et al. (2010) A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56:34-43
20. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C (2008) Relationship between serum adiponectin and prostate cancer grade. Prostate 68:1592-1598
21. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E (2009) Serum adipocytokine levels in prostate cancer patients. Urol Int 82:203-208
22. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65:1168-1172
23. Freedland SJ, Sokoll LJ, Platz EA, et al. (2005) Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 174:1266-1270
24. Housa D, Vernerova Z, Heracek J, et al. (2008) Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 57:451-458
25. Baillargeon J, Platz EA, Rose DP, et al. (2006) Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 15:1331-1335
26. Lopez Fontana CM, Maselli ME, Perez Elizalde RF, Di Milta Monaco NA, Uvilla Recupero AL, Lopez Laur JD (2011) Leptin increases prostate cancer aggressiveness. J Physiol Biochem 67:531-538
27. Chang S, Hursting SD, Contois JH, et al. (2001) Leptin and prostate cancer. Prostate 46:62-67
28. Saglam K, Aydur E, Yilmaz M, Goktas S (2003) Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169:1308-1311
29. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2005) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588
30. Neuhouser ML, Till C, Kristal A, et al. (2010) Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res 3:279-289
31. Freedland SJ, Sokoll LJ, Mangold LA, et al. (2005) Serum leptin and pathological findings at the time of radical prostatectomy. J Urol 173:773-776
32. Singh SK, Grifson JJ, Mavuduru RS, Agarwal MM, Mandal AK, Jha V (2010) Serum leptin: a marker of prostate cancer irrespective of obesity. Cancer Biomarkers 7:11-15
33. Stocks T, Lukanova A, Rinaldi S, et al. (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 120:2678-2686
34. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46:3095-3101
35. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V (2000) Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-α and leptin. Cytokine 12:1712-1716
36. Godin G, Shephard RJ (1985) A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 10:141-146
37. Royston P, Altman DG (1994) Regression using fractional polynomials of continuous covariates - parsimonious parametric modeling. Appl Stat J R St C 43:429-467
38. Andersson SO, Wolk A, Bergstrom R, et al. (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. JNCI 89:385-389
39. Rodriguez C, Freedland SJ, Deka A, et al. (2007) Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 16:63-69
40. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88-97
41. Onuma M, Bub JD, Rummel TL, Iwamoto Y (2003) Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278:42660-42667
42. Hoda MR, Popken G (2008) Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int 102:383-388
43. Laur JL, Elizalde RP, Crica A, et al. (2010) Relationship between obesity and adipokines with prostate cancer prevalence and aggressiveness. J Urol Conf e667
44. Ma J, Li H, Giovannucci E, et al. (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039-1047
45. Zakikhani M, Pollak M. (2007) Adiponectin and metformin inhibit prostate and colon cancer cell proliferation via AMP kinase (AMPK) - dependent mechanisms. In: Proceedings of the American Association for Cancer Research Annual Meeting, vol 48, p 1058
46. Wright J, Stanford J (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20:1617-1622
47. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes impact of metformin on survival. Diabetes Care 35:299-304
48. Kaklamani V, Yi NJ, Zhang K, et al. (2011) Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metab, Clin Exp 60:1234-1243
49. Hsing AW, Sakoda LC, Chua SC Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86:843S-8857
50. Lee SA, Kallianpur A, Xiang YB, et al. (2007) Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 16:2464-2470
51. Thompson IM, Pauler DK, Goodman PJ, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level< or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246
52. Stark JR, Perner S, Stampfer MJ, et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459-3464
53. Chan TY, Partin AW, Walsh PC, Epstein JI (2000) Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 56:823-827